Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Chemoimmunotherapy in ES-SCLC with Liver Metastases
NCT05588388Phase 2Recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in small cell lung cancer (SCLC). Started Aug 2024; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05588388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588388.